ISB News

Baliga Lab: Uncovering the Genetic Adaptability of Tuberculosis

3 Bullets:

  • The Institute for Systems Biology and Seattle BioMed have collaborated to reconstruct the gene regulatory network of the human pathogen Mycobacterium tuberculosis.
  • Finely tuned gene regulation has allowed Mycobacterium tuberculosis to survive unnoticed in an apparently healthy host for decades; understanding those subtleties is critical for advancing treatment.
  • The identification of co-regulated sets of genes and their regulatory influences offers validated predictions that will help guide future research into Mycobacterium tuberculosis pathogenicity.

By Jake Valenzuela and Eliza Peterson

Tuberculosis, responsible for nearly two million deaths each year, is caused by the bacterium Mycobacterium tuberculosis (MTB). Researchers from the Institute of Systems Biology in collaboration with Seattle BioMed have undertaken a comprehensive approach centered around the strengths of systems biology to identify adaptive regulatory mechanisms employed by MTB.

Journal: Nucleic Acids Research
Title: A high-resolution network model for global gene regulation in Mycobacterium tuberculosis
Authors: Eliza J.R. Peterson, David J. Reiss, Serdar Turkarslan, Kyle J. Minch, Tige Rustad, Christopher L. Plaisier, William J.R. Longabaugh, David R. Sherman, Nitin S. Baliga
Link: http://nar.oxfordjournals.org/content/early/2014/09/17/nar.gku777.full

The success of MTB as a human pathogen is largely due to its ability to alter gene expression and adapt to the complex host environment within which it resides. In an effort to model the gene regulation of this elusive microorganism, researchers compiled 2,325 publicly available gene expression profiles from a diverse set of conditions and constructed a gene regulatory network model of MTB. The gene regulatory network model predicts sets of genes that are similarly expressed, the proteins or factors that bind to DNA to influence their gene expression, and the environmental conditions in which these regulatory interactions occur. This global analysis gives us a clearer idea of MTB pathogenicity and, by engaging in a systems biology approach, we better understand how the pathogen responds to a diversity of stress conditions like low oxygen, host interactions, and nutrient availability. In particular, the researchers highlighted the importance of host cholesterol availability during infection and provided new details about the regulation of cholesterol utilization in MTB.

Importantly, the gene regulatory network of MTB was made publicly available (http://networks.isbscience.net/mtb/) to encourage exploration of the model. This will hopefully drive future efforts toward understanding how MTB responds to various environmental conditions, including those responsible for pathogenicity. This network also laid the foundation for future versions of the model that will incorporate new data and new modeling techniques.

Read more about ISB’s work with Tuberculosis: ISB Researchers Identify New Protein Modification Critical Growth of Tuberculosis Pathogen

About Dr. Jake Valenzuela and Dr. Eliza Peterson: Jake is a postdoc in the Baliga Lab and a member of the ISB Editorial Board. Eliza is postdoc in the Baliga Lab and lead author of the paper.

Recent Articles

  • Timing is Everything: ISB Study Finds Link Between Bowel Movement Frequency and Overall Health

    Everybody poops, but not every day. An ISB-led research team examined the clinical, lifestyle, and multi-omic data of more than 1,400 healthy adults. How often people poop, they found, can have a large influence on one’s physiology and health.

  • Wei Wei, PhD

    Dr. Wei Wei Promoted to Associate Professor

    Wei Wei, PhD – an accomplished cancer researcher with expertise in biotechnology and cancer systems biology – has been promoted to ISB associate professor. The Wei Lab focuses on understanding how cancer cells adapt to therapeutic treatment to foster therapy resistance by coordinating their internal molecular machinery and how these adaptive changes evolve within diverse tumors influenced by the tumor microenvironment. 

  • Drs. Nitin Baliga and James Park

    How Glioblastoma Resists Treatment – and Ways to Prevent It

    Glioblastoma is one of the deadliest and most aggressive forms of primary brain cancer in adults and is known for its ability to resist treatment and to recur. ISB researchers have made breakthrough discoveries in understanding the mechanisms behind acquired resistance, focusing on a rare and stubborn group of cells within tumors called glioma stem-like cells.